MediciNova, Inc.

MNOV · Nasdaq · United States

Share price · MNOV

$1.33-0.01 (-0.75%) 3M

close as of 2026-11-18 · 24h delayed · vol 116K (1.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MNOV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026-18.6%
  2. 22 Sep 2026-12.1%
  3. 17 Sep 2026+36.9%
  4. 16 Sep 2026+24.8%
  5. 15 Sep 2026+8.0%
  6. 8 Sep 2026+7.4%
  7. 3 Sep 2026+13.3%
  8. 24 Aug 2026+10.1%
  9. 17 Jul 2026-4.9%

    Nothing announced by MNOV that day or the session before.

  10. 1 Jul 2026+7.6%

Share of unusual movement by asset

For each asset, the share of MNOV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tipelukast
events and moves
2shown from 8 days
Ibudilast
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—94%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
PDE4 and PDE10; macrophage migration inhibitory factor (MIF)Small molecule
AsthmaAmyotrophic Lateral Sclerosis
Phase 2
Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenaseSmall molecule
Type 2 DiabetesMASH / NASHCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TipelukastPhase 2Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Est. primary completion 2026-12-31 · NCT05464784 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
IbudilastPhase 2/3Amyotrophic Lateral Sclerosis
Est. primary completion 2027-04 · NCT04057898 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 September 2026Topline resultTipelukastPhase 2 MN-001-NATG-202 topline: Week 24 triglyceride and liver-fat changes not statistically significant vs placebo
MediciNova, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.1M$1.1M$29M$2.8M-$2.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.5M$0.9M$25M$2.3M-$1.9M operating cash flowreport ↗
2026-Q1$0.2M$1.2M$27M$2.6M-$3.5M operating cash flowreport ↗
2025-Q3$0.1M$1.5M$33M$3.0M-$1.7M operating cash flowreport ↗
2025-Q2$0.1M$2.0M$34M$3.3M-$2.3M operating cash flowreport ↗
2025-Q1—$1.7M$37M$2.9M-$3.8M operating cash flowreport ↗
2024-Q3—$1.8M$42M$2.9M-$2.0M operating cash flowreport ↗
2024-Q2—$1.5M$44M$2.6M-$2.8M operating cash flowreport ↗
2024-Q1—$1.7M$47M$2.8M-$3.9M operating cash flowreport ↗
2023-Q3$1.0M$0.7M$52M$0.7M-$1.4M operating cash flowreport ↗
2023-Q2—$1.6M$53M$2.9M-$2.4M operating cash flowreport ↗
2023-Q1—$1.4M$55M$2.9M-$3.2M operating cash flowreport ↗
2022-Q3—$2.4M$53M$3.6M-$2.7M operating cash flowreport ↗
2022-Q2—$2.5M$65M$4.0M-$2.5M operating cash flowreport ↗
2022-Q1—$2.0M$68M$3.4M-$3.7M operating cash flowreport ↗
2021-Q3<$0.1M$2.0M$75M$3.6M-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.4M$6.7M$31M$3.0M-$9.8M operating cash flowreport ↗

For FY2025, MediciNova reported revenue of $0.41M, with no revenue recorded in the prior year. R&D spend was $6.7M, down 1.5% YoY, and cash and equivalents totaled $30.81M, with a net loss of $12M for the year.

The company did not provide a consolidated forecast for FY2026, citing ongoing strategic collaboration and out-licensing activities, but anticipated FY2026 operating expenses of approximately $16.2M, up 18% versus FY2025, with R&D spend expected to increase due to ongoing clinical trials. Development continues on MN-166 (ibudilast) for progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and ARDS prevention, and on MN-001 (tipelukast) for NAFLD and hypertriglyceridemia. During 2025, the company recognized revenue under its Mayo Foundation agreement, entered into a standby equity purchase agreement with Yorkville and an equity distribution agreement with Lucid, and in January 2026 granted 980,000 stock options to executive officers.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$6.8M$40M$2.8M-$11M operating cash flowreport ↗
2023-FY$1.0M$5.3M$51M$2.1M-$7.4M operating cash flowreport ↗
2022-FY—$8.7M$19M+ $40M short-term inv.$3.5M-$13M operating cash flowreport ↗
2021-FY$4.0M$8.1M$71M$2.5M-$9.4M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($1.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-253D Investment Partners Pte. Ltd.; 3D Opportunity Master Fund · Formerly 10% Owner; Formerly 10% OwnerOpen-market sale640,000$2.70$1.7MForm 4
2026-06-23BEAVER CAROLYN · directorAward / grant (derivative)44,500——Form 4
2026-06-23Lemerond Nicole · directorAward / grant (derivative)44,500——Form 4
2026-06-23Nagao Hideki · directorAward / grant (derivative)44,500——Form 4
2026-01-16IWAKI YUICHI · President and CEOAward / grant (derivative)450,000——Form 4
2026-01-16Matsuda Kazuko · Chief Medical OfficerAward / grant (derivative)350,000——Form 4
2025-06-17BEAVER CAROLYN · directorAward / grant (derivative)20,000——Form 4
2025-06-17Lemerond Nicole · directorAward / grant (derivative)20,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 30 reporting institutions held 5.4M shares ($7.4M, 11.0% of shares outstanding).

#InstitutionSharesValue
1Essex Woodlands Management, Inc.1,105,941$1.5M
2BlackRock, Inc.705,954$967K
3CITIGROUP INC635,715$871K
4VANGUARD CAPITAL MANAGEMENT LLC611,039$837K
5GEODE CAPITAL MANAGEMENT, LLC543,843$745K
6VANGUARD FIDUCIARY TRUST CO280,621$384K
7UBS Group AG222,200$304K
8STATE STREET CORP193,698$265K
9RENAISSANCE TECHNOLOGIES LLC189,900$260K
10BARCLAYS PLC162,900$223K
11NORTHERN TRUST CORP133,163$182K
12JANE STREET GROUP, LLC87,085$119K
13Bank of New York Mellon Corp78,277$107K
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC71,506$98K
15BRIDGEWAY CAPITAL MANAGEMENT, LLC56,031$77K